ZYNE 0.00 Zynerba Pharmaceuticals, Inc.
| Range: | 0.25-1.4 | Vol Avg: | 1043239 | Last Div: | 0 | Changes: | 0.03 |
| Beta: | 1.19 | Cap: | 0.07B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Aug 05 2015 | Empoloyees: | 25 | ||
| CUSIP: | 98986X109 | CIK: | 0001621443 | ISIN: | US98986X1090 | Country: | US |
| CEO: | Mr. Armando Anido MBA | Website: | https://www.zynerba.com | ||||
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow